Terms: = Ovarian cancer AND KLF6, RP11-184A2_1, 1316, ENSG00000067082, ST12, DKFZp686N0199, CPBP, Zf9, COPEB, ZF9, PAC1, GBF, BCD1 AND Treatment
12578 results:
1. Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer.
Erturk A; Korkmaz E; Arslantas Z; Bekdemir S; Erturk NK
Rev Assoc Med Bras (1992); 2024; 70(5):e20231115. PubMed ID: 38775501
[TBL] [Abstract] [Full Text] [Related]
2. Racial and Ethnic Inequities in cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2.
Islam JY; Hathaway CA; Hume E; Turner K; Hallanger-Johnson J; Tworoger SS; Camacho-Rivera M
JAMA Netw Open; 2024 May; 7(5):e2412050. PubMed ID: 38767916
[TBL] [Abstract] [Full Text] [Related]
3. Construction and Validation of a Nomogram to Predict the Postoperative Venous Thromboembolism Risk in Patients with HGSOC.
Huang Z; Li L; Gong Z; Tang L
Clin Appl Thromb Hemost; 2024; 30():10760296241255958. PubMed ID: 38767088
[TBL] [Abstract] [Full Text] [Related]
4. Fertility preservation in female cancer patients in Brazil: perceptions and attitudes of infertility specialists.
Ranniger RL; Lamaita RM; D'Abreu BF; Tolentino MR; Cândido EB; Andrade WP; Nogueira-Rodrigues A; Silva-Filho AL
Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 38765513
[TBL] [Abstract] [Full Text] [Related]
5. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
6. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
[TBL] [Abstract] [Full Text] [Related]
7. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
[TBL] [Abstract] [Full Text] [Related]
8. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
10. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.
Nan Y; Wu X; Luo Q; Chang W; Zhao P; Zhang L; Liu Z
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2315348121. PubMed ID: 38701117
[TBL] [Abstract] [Full Text] [Related]
11. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract] [Full Text] [Related]
12. A Novel Non-Psychoactive Fatty Acid from a Marine Snail,
Vijayaraghavan CS; Raman LS; Surenderan S; Kaur H; Chinambedu MD; Thyagarajan SP; Gnanambal Krishnan ME
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675558
[TBL] [Abstract] [Full Text] [Related]
13. TCEB3 initiates ovarian cancer apoptosis by mediating ubiquitination and degradation of MCL-1.
Cai Y; Li Y; Xu Y; Yang W; Huang M
FASEB J; 2024 Apr; 38(8):e23625. PubMed ID: 38661028
[TBL] [Abstract] [Full Text] [Related]
14. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
[TBL] [Abstract] [Full Text] [Related]
15. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Friedman CF; Manning-Geist BL; Zhou Q; Soumerai T; Holland A; Da Cruz Paula A; Green H; Ozsoy MA; Iasonos A; Hollmann T; Leitao MM; Mueller JJ; Makker V; Tew WP; O'Cearbhaill RE; Liu YL; Rubinstein MM; Troso-Sandoval T; Lichtman SM; Schram A; Kyi C; Grisham RN; Causa Andrieu P; Wherry EJ; Aghajanian C; Weigelt B; Hensley ML; Zamarin D
Nat Med; 2024 May; 30(5):1330-1338. PubMed ID: 38653864
[TBL] [Abstract] [Full Text] [Related]
16. Granulosa cell tumor of the ovary: a series of 6 cases.
da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
[TBL] [Abstract] [Full Text] [Related]
17. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
18. Small bite fascial closure technique reduces incisional hernia rates in gynecologic oncology patients.
Straubhar AM; Stroup C; Manorot A; McCool K; Rolston A; Reynolds RK; McLean K; de Bear O; Siedel J; Uppal S
Int J Gynecol Cancer; 2024 May; 34(5):745-750. PubMed ID: 38642924
[TBL] [Abstract] [Full Text] [Related]
19. Deciphering a GPCR-lncrna-miRNA nexus: Identification of an aberrant therapeutic target in ovarian cancer.
Ha JH; Radhakrishnan R; Nadhan R; Gomathinayagam R; Jayaraman M; Yan M; Kashyap S; Fung KM; Xu C; Bhattacharya R; Mukherjee P; Isidoro C; Song YS; Dhanasekaran DN
Cancer Lett; 2024 Jun; 591():216891. PubMed ID: 38642607
[TBL] [Abstract] [Full Text] [Related]
20. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
[Next]
